ConductScience.org, home

Comparison · NCT03436732-deaths

140 mcg/kg LMB-100 + SEL-110 vs 100 mcg/kg LMB-100 + SEL-110: deaths from any cause

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. 140 mcg/kg LMB-100 + SEL-110 vs 100 mcg/kg LMB-100 + SEL-110: deaths from any cause. Trial comparisons, record NCT03436732-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03436732-deaths

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.50.150.85wilson
Risk in group 210.2071wilson
Risk difference, group 1 minus group 2-0.5-0.850.367newcombe hybrid score
Risk ratio, group 1 over group 20.50.1881.33log
Odds ratio, group 1 over group 2loga cell of the two-by-two table is zero
Number needed to treat, for one fewer death from any cause on 140 mcg/kg LMB-100 + SEL-110 than on 100 mcg/kg LMB-100 + SEL-1102from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1140 mcg/kg LMB-100 + SEL-110
Dose escalation - patients with mesothelioma treated with LMB-100+SEL-110 at escalating doses~LMB-100: administered on days 1, 3 and 5 of each 21 day cycle for up to 4 cycles~SEL-110: administered on day 1 of each cycle for up to 4 cycles
24EG000
Group 2100 mcg/kg LMB-100 + SEL-110
Dose escalation - patients with mesothelioma treated with LMB-100+SEL-110 at escalating doses~LMB-100: administered on days 1, 3 and 5 of each 21 day cycle for up to 4 cycles~SEL-110: administered on day 1 of each cycle for up to 4 cycles
11EG001

Harm

What it counts
Total, all-cause mortality
Time frame
Date treatment consent signed to date off study, approximately one month and 25 days for the 100 mcg/kg Arm/Group, and 9 months and 28 days for the 140 mcg/kg Arm/Group.

Source ClinicalTrials.gov

Trial

Title
Mesothelin-Targeted Immunotoxin LMB-100 in Combination With SEL-110 in Subjects With Malignant Pleural or Peritoneal Mesothelioma
NCT number
NCT03436732
Phases
PHASE1
Conditions
Mesothelioma
Interventions
LMB-100, SEL-110
Lead sponsor
National Cancer Institute (NCI)
Results first posted
2019-11-22

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT03436732-deaths